Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

ByConnor Hodde

WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years…

Study Findings Help Design Next-Generation Nanocarriers

ByConnor Hodde

Researchers believe that atomic-scale design of pharmaceuticals will be instrumental in producing more accurate and efficient drugs. Nanocarriers are engineered particles capable of holding tiny molecules inside their hollow interiors. Antibodies, which are bonded to the outer surface of these nanocarriers, function as markers to target specific cells or tissues or supply drugs to infected…